A5100654897- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Systemic Lupus Erythematosus Research
- CNS Lymphoma Diagnosis and Treatment
- Homelessness and Social Issues
- Ocular Diseases and Behçet’s Syndrome
- Criminal Justice and Corrections Analysis
- Pain Management and Opioid Use
- Polyomavirus and related diseases
- Neuroinflammation and Neurodegeneration Mechanisms
- Retinal and Optic Conditions
- Migration, Health and Trauma
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Rheumatoid Arthritis Research and Therapies
- Immunotherapy and Immune Responses
- Hereditary Neurological Disorders
- Systemic Sclerosis and Related Diseases
- T-cell and B-cell Immunology
- Palliative Care and End-of-Life Issues
- HIV, Drug Use, Sexual Risk
- Viral Infections and Immunology Research
- Long-Term Effects of COVID-19
- Tuberculosis Research and Epidemiology
- Celiac Disease Research and Management
Harvard University
2016-2025
Massachusetts General Hospital
2016-2025
Université Paris Cité
2024
Assistance Publique – Hôpitaux de Paris
2024
Impact
2024
Johns Hopkins University
2013-2022
Johns Hopkins Medicine
2011-2022
Mayo Clinic in Arizona
2015-2022
Icahn School of Medicine at Mount Sinai
2022
Queen Mary University of London
2019-2022
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or extensive may occur. The International Panel for Diagnosis (IPND) was convened to develop revised using systematic literature reviews electronic surveys facilitate consensus. new nomenclature defines the unifying term...
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) complement-mediated damage to central nervous system. In previous small, open-label study involving patients AQP4-IgG–positive disease, eculizumab, terminal complement inhibitor, was shown reduce frequency relapse.
To provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors.An ASCO-convened expert panel conducted a systematic literature search studies investigating survivors. Outcomes interest included symptom relief, intensity, quality life, functional outcomes, adverse events, misuse or diversion, and risk assessment mitigation.A total 63 met eligibility criteria compose evidentiary basis for recommendations. Studies tended to be heterogeneous terms quality,...
Post-mortem ganglion cell dropout has been observed in multiple sclerosis; however, longitudinal vivo assessment of retinal neuronal layers following acute optic neuritis remains largely unexplored. Peripapillary nerve fibre layer thickness, measured by optical coherence tomography, proposed as an outcome measure studies neuroprotective agents sclerosis, yet potential swelling during the stages may confound baseline measurements. The objective this study was to ascertain whether patients...
Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness paralysis. Effective immunosuppression standard care for relapse prevention.To compare treatment failure rates among patients receiving 3 most common forms NMO: azathioprine, mycophenolate mofetil, rituximab.We performed a retrospective, multicenter analysis relapses in 90 with NMO spectrum disorder treated mycophenolate, and/or rituximab at Mayo Clinic Johns Hopkins Hospital...
Rare diseases require integrated multicenter clinical networks to facilitate research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that distinct from multiple sclerosis associated with NMO-IgG, a serologic antibody against aquaporin 4.To develop national consortium report initial demographic, clinical, radiographic features of cohort patients NMO/NMOSD in the United States.Review medical records undergoing evaluation during 5-year...
Although adding plasma exchange (PLEX) to steroids in severe neuromyelitis optica (NMO) attacks is common practice steroid-resistant cases, the benefit of this strategy has not been previously quantified.The objective paper compare efficacy high-dose intravenous methylprednisolone (IVMP) versus IVMP+PLEX treatment acute NMO relapses.We conducted a retrospective review last 83 admissions Johns Hopkins Hospital treated with IVMP alone (for cases). Extended Disability Status Scale (EDSS) score...
Maria was distraught after reading about the 'potential' epidemic, yet to happen, and horror stories on Facebook needing reassurance certainty what she should do. She requested an urgent appointment review her treatment plan. a 26-year-old woman with relapsing multiple sclerosis who had recently experienced brainstem relapse double vision ataxia despite pegylated interferon-beta for last 18 months. A brain MRI performed one month prior shown 16 new T2 lesions, four of which were enhancing....
CHAMPION-NMOSD (NCT04201262) is a phase 3, open-label, externally controlled interventional study evaluating the efficacy and safety of terminal complement inhibitor ravulizumab in adult patients with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds same component 5 epitope as approved therapeutic eculizumab but has longer half-life, enabling an extended dosing interval (8 vs 2 weeks).The availability precluded use concurrent...
Recent studies suggest that maintenance intravenous immunoglobulin (IVIG) may be an effective treatment to prevent relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); however, most of these had pediatric cohorts, and few have evaluated IVIG adult patients.To determine the association with prevention relapse a large cohort patients MOGAD.This was retrospective study conducted from January 1, 2010, October 31, 2021. Patients were recruited 14 hospitals 9...
Background: Neuromyelitis optica (NMO) is a severe autoimmune disease of the central nervous system characterized by spinal cord and optic nerve involvement. Brainstem manifestations have recently been described. Objective: To evaluate time occurrence, frequency characteristics brainstem symptoms in cohort patients with NMO according to ethnic background serologic status for anti-aquaporin-4 antibodies (AQP4-abs). Methods: We performed multicenter study 258 2006 Wingerchuk criteria we...
In the United States, a total of 1,479,350 new cancer cases and 562,340 deaths from were estimated to occur in 2009. 1 All patients experience some level distress associated with diagnosis treatment at all stages disease.Surveys have found that 20% 40% newly diagnosed recurrent show significant distress. 2However, fewer than 10% are actually identified referred for psychosocial help. 3any who need care not able get help they due under recognition patient's psychological needs by primary...
We aimed to evaluate racial differences in the clinical features of neuromyelitis optica spectrum disorder.This retrospective review included 603 patients (304 Asian, 207 Caucasian, and 92 Afro-American/Afro-European), who were seropositive for anti-aquaporin-4 antibody, from 6 centers Denmark, Germany, South Korea, United Kingdom, States, Thailand.Median disease duration at last follow-up was 8 years (range 0.3-38.4 years). Asian Afro-American/Afro-European had a younger onset age than...
<h3>Objective</h3> To define the frequency, duration, and severity of intractable nausea, vomiting, or hiccups in aquaporin-4–immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) propose diagnostic criteria a scale for area postrema syndrome (APS). <h3>Methods</h3> An International NMOSD database was interrogated frequency APS. Patients with AQP4-IgG–positive completed an APS symptom questionnaire. Nausea vomiting derived from Pregnancy-Unique Quantification...